Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
The Pleasanton Police Department is warning residents of a “possible foreign substance” reported in banana bread being sold throughout the city.Police warn of banana bread with ‘possible foreign substance’ being sold in PleasantonBexar County Medical Examiner’s Office identifies woman fatally shot on Northwest Side Read full article: Bexar County Medical Examiner’s Office identifies woman fatally shot on Northwest Side‘I feel like I’ve lost everything’: Live Oak woman says nearby construction contributed to flooding Read full article: ‘I feel like I’ve lost everything’: Live Oak woman says nearby construction contributed to floodingSan Antonio River Authority addresses concerns after deadly floods, focusing on prevention and future safetyDual USB-C + USB-A 3.
2 High Speed Flash Drive FILE - The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed, Oct. 14, 2015. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant ofElevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading., might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the “Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,” said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.Dual USB-C + USB-A 3.2 High Speed Flash Drive
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UnitedHealth shares fall after HSBC downgrades rating, says shares not cheap enoughShares have pulled back more than 36% in 2025.
Read more »
Erin Andrews Shares Surrogate's Miscarriage With Second BabyErin Andrews shared that her surrogate experienced a miscarriage with her second baby, detailing her continued fertility journey challenges
Read more »
CoreWeave shares slump nearly 10% in second day of tradingCoreWeave rents out access to Nvidia graphics processing units to other large tech and AI companies including Meta, IBM and Cohere.
Read more »
Stocks making the biggest moves premarket: U.S. Steel, Roku, Celsius, Sarepta Therapeutics and moreThese are some of the stocks posting the largest moves in early trading Monday.
Read more »
Second patient death reported with gene therapy for muscular dystrophyShares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
Read more »
Second patient death reported with gene therapy for muscular dystrophyShares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
Read more »